STOCKWATCH: Waiting for the biotech bubble to burst
This article was originally published in Scrip
Everybody's wondering, when will the biotech bubble burst? Whilst there have been IPOs cancelled citing "market conditions", news of many more primary and secondary offerings continues to appear in our in boxes. Logic dictates that the bubble will burst eventually and indeed in the last year we've already had two warning pops caused by drug pricing concerns, but the NASDAQ Biotech Index has continued its relentless climb. Even so, fresh evidence is appearing that the bubble is about to die, starting with this latest earnings season
You may also be interested in...
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.